Core Viewpoint - The company, Gongtong Pharmaceutical (300966.SZ), has announced a share buyback program, indicating a strategic move to enhance shareholder value and confidence in the company's future prospects [1] Group 1: Share Buyback Details - The company has repurchased a total of 1,069,600 shares, which represents 0.9278% of its current total share capital [1] - The highest transaction price during the buyback was 22.25 CNY per share, while the lowest was 13.15 CNY per share [1] - The total amount spent on the buyback was 21,969,816.00 CNY, excluding transaction fees [1]

| 证券代码：300966 | 证券简称：共同药业 | 公告编号：2025-059 | | --- | --- | --- | | 转债代码：123171 | 转债简称：共同转债 | | 湖北共同药业股份有限公司 关于回购公司股份进展暨股份变动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 湖北共同药业股份有限公司（以下简称"公司"）于 2025 年 2 月 20 日召开第 三届董事会第三次会议、第三届监事会第三次会议，审议通过了《关于回购公司股 份方案的议案》，同意公司使用自有资金及股票回购专项贷款资金以集中竞价交易 方式回购公司已发行的股份，用于股权激励或员工持股计划。本次回购总金额不低 于人民币 2,000 万元（含）且不超过人民币 3,000 万元（含），回购价格不超过 23.84 元/股，具体回购资金总额以回购期满时实际回购股份使用的资金总额为准，回购期 限为董事会审议通过该回购股份方案之日起 12 个月内。具体内容详见公司于 2025 年 2 月 20 日、2025 年 2 月 26 日在巨潮资讯网（www.cninfo.com.cn）上披 ...

Core Insights - The company is actively expanding its overseas market presence, with product exports projected to increase from 28.54% in 2024 to 38.6% by mid-2025 [2] - A joint venture with Huahai Pharmaceutical is focused on high-end steroid raw material production, with two production workshops already in trial production [3] - The company is leveraging synthetic biology technology to optimize processes and enhance customer collaboration in response to global pharmaceutical supply chain restructuring [5] Overseas Market Expansion and Future Plans - The company's export ratio is on the rise, with a target of 28.54% for 2024 and an increase to 38.6% by mid-2025 [2] - The company aims to strengthen brand promotion and sales channels through overseas subsidiaries and local partnerships [2] Raw Material Layout and Progress - The joint venture, Huahai Gongtong, aims to integrate strengths for high-end steroid raw material production, with plans divided into two phases covering 13 products [3] - Two production workshops are in trial production, with another set to begin soon, and preparations for registration documentation are underway [3] Applications of Steroid Products - Steroid drugs are categorized into sex hormones, progestogens, corticosteroids, and others, with applications in hormone replacement, disease treatment, and inflammation management [4] - The range of products and applications is continuously expanding [4] Response to Supply Chain Restructuring and Core Competitiveness - The global restructuring of the pharmaceutical supply chain is influencing the company's capacity layout and customer collaboration models [5] - The company views full supply chain collaboration as a core competitive advantage, enhancing efficiency across starting materials, intermediates, and raw materials [5] Plans for High-Value-Added Fields - Over the next 2-3 years, the company plans to extend into high-value-added areas, leveraging its complete industrial chain and professional R&D platform [6] - The focus will be on high-end intermediates and customized products [6]

Group 1: Company Overview and Market Expansion - The company's overseas market expansion has seen an increase in product export ratio from 28.54% in 2024 to 38.6% in the first half of 2025, indicating a consistent upward trend in international sales [2] - The primary overseas markets include Europe, North America, South America, and India [3] Group 2: Product Development and Production - The joint venture with Huahai Pharmaceutical focuses on high-end steroid raw materials, with a total of 13 high-end steroid raw material products planned, and two production workshops have entered trial production [3][4] - The company aims to enhance production efficiency and product quality by applying synthetic biology and other technologies [5] Group 3: Market Applications and Trends - Steroid drugs are categorized into sex hormones, progestogens, corticosteroids, and others, with applications in hormone replacement therapy, immune response treatment, and chronic disease management [4] - The restructuring of the global pharmaceutical supply chain presents new opportunities, particularly in reproductive health and chronic disease management for the aging population [5] Group 4: Competitive Strategy - The company emphasizes full supply chain collaboration as a core competitive advantage, focusing on optimizing raw material sourcing, intermediate production, and raw material drug development [5] - Plans to extend into high-value areas such as high-end intermediates and specialty raw materials are underway, supported by a complete industrial chain from steroid drug raw materials to intermediates and APIs [5]

Core Viewpoint - The company, Gongtong Pharmaceutical, has conducted a share buyback, acquiring a total of 968,400 shares, which represents 0.84% of its current total share capital, in compliance with relevant laws and its established buyback plan [1] Summary by Relevant Sections - **Share Buyback Details** - The company repurchased shares through a special securities account via centralized bidding [1] - The highest transaction price was 22.25 CNY per share, while the lowest was 13.15 CNY per share [1] - The total amount spent on the buyback was 19,768,280.00 CNY, excluding transaction fees [1]

Group 1 - The company, Gongtong Pharmaceutical, announced a share buyback program, repurchasing approximately 970,000 shares, which represents 0.84% of its total share capital, with a total transaction amount of about 19.77 million yuan [1] - The highest transaction price during the buyback was 22.25 yuan per share, while the lowest was 13.15 yuan per share [1] - As of the report, Gongtong Pharmaceutical's market capitalization stands at 2.5 billion yuan [1] Group 2 - For the first half of 2025, the company's revenue composition shows that steroid drug raw material manufacturing accounts for 99.91%, while other businesses contribute only 0.09% [1]

| 证券代码：300966 | 证券简称：共同药业 | 公告编号：2025-058 | | --- | --- | --- | | 转债代码：123171 | 转债简称：共同转债 | | 湖北共同药业股份有限公司 截至 2025 年 9 月 30 日，公司本次通过股份回购专用证券账户以集中竞价交易 方式累计回购公司股份 968,400 股，占公司当前总股本的 0.84%，最高成交价为 22.25 元/股，最低成交价为 13.15 元/股，成交总金额为 19,768,280.00 元（不含交易费用）。 公司本次回购股份符合相关法律法规的要求和公司既定的回购股份方案。 二、其他说明 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 湖北共同药业股份有限公司（以下简称"公司"）于 2025 年 2 月 20 日召开第 三届董事会第三次会议、第三届监事会第三次会议，审议通过了《关于回购公司股 份方案的议案》，同意公司使用自有资金及股票回购专项贷款资金以集中竞价交易 方式回购公司已发行的股份，用于股权激励或员工持股计划。本次回购总金额不低 于人民币 2,000 万元（含） ...

| 证券代码：300966 | 证券简称：共同药业 | 公告编号：2025-057 | | --- | --- | --- | | 转债代码：123171 | 转债简称：共同转债 | | 湖北共同药业股份有限公司 关于2025年第三季度可转换公司债券转股情况的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、"共同转债"（债券代码：123171）的转股期限为 2023 年 6 月 2 日至 2028 年 11 月 27 日；最新的转股价格为人民币 27.12 元/股。 2、2025 年第三季度，共有 453 张"共同转债"（票面金额共计 45,300 元人民 币）完成转股，合计转成 1,661 股"共同药业"（股票代码：300966）股票。 3、截至 2025 年第三季度末，公司剩余可转债为 3,798,888 张，剩余票面总额为 379,888,800 元人民币。 根据《深圳证券交易所创业板股票上市规则》和《深圳证券交易所上市公司自 律监管指引第 15 号——可转换公司债券》的有关规定，湖北共同药业股份有限公司 （以下简称"公司"）现将 ...

Core Points - The company announced that it will not lower the conversion price of its convertible bonds during the specified period [2] - The board of directors decided that if the conditions for lowering the conversion price are triggered again after March 24, 2026, a new meeting will be held to determine whether to exercise the right to lower the conversion price [2] Summary by Sections - **Company Decision**: The company held a board meeting on September 23, 2025, where it approved the proposal not to lower the conversion price of its convertible bonds [2] - **Future Conditions**: The company will not propose a downward adjustment of the conversion price until March 23, 2026, even if the conditions are met [2] - **Post-2026 Review**: After March 24, 2026, if the conditions for a downward adjustment are triggered again, the board will reconvene to decide on the matter [2]

| 证券代码：300966 | 证券简称：共同药业 | 公告编号：2025-055 | | --- | --- | --- | | 转债代码：123171 | 转债简称：共同转债 | | 湖北共同药业股份有限公司 第三届董事会第九次会议决议公告 综合考虑公司的基本情况、市场环境等诸多因素，以及对公司长期稳健发展与 内在价值的信心，董事会决定本次不向下修正"共同转债"转股价格，同时自本次 董事会审议通过次一交易日起至 2026 年 3 月 23 日，如再次触发"共同转债"转股 价格向下修正条件，亦不提出向下修正方案。在此期间之后（从 2026 年 3 月 24 日 1 重新起算），若再次触发"共同转债"转股价格向下修正条件，届时公司董事会将 再次召开会议决定是否行使"共同转债"的转股价格向下修正权利。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 湖北共同药业股份有限公司（以下简称"公司"）第三届董事会第九次会议于 2025 年 9 月 23 日在公司会议室以现场结合通讯表决的方式召开。会议通知及材料于 2025 年 9 月 19 日以 ...